Advertisement

European Journal of Clinical Pharmacology

, Volume 71, Issue 2, pp 209–217 | Cite as

Hematological safety of metamizole: retrospective analysis of WHO and Swiss spontaneous safety reports

  • Lea S. Blaser
  • Alexandra Tramonti
  • Pascal Egger
  • Manuel Haschke
  • Stephan KrähenbühlEmail author
  • Alexandra E. Rätz Bravo
Pharmacoepidemiology and Prescription

Abstract

Purpose

Since the 1970s, the use of metamizole is controversial due to the risk of agranulocytosis. The aim of this study was to analyze individual case safety reports (ICSRs) of metamizole-associated hematological adverse drug reactions (ADRs).

Methods

International and Swiss metamizole-associated ICSR concerning selected hematological ADR were retrieved from VigiBase™, the World Health Organization Global Database of ICSR, and the Swiss Pharmacovigilance Database. We evaluated demographic data, co-medication, drug administration information, dose and duration of metamizole treatment, as well as the latency time of ADR, their course, and severity. The subgroup analysis of Swiss reports allowed us to analyze cases with fatal outcome more in depth and to estimate a rough minimal incidence rate.

Results

A total of 1417 international and 77 Swiss reports were analyzed. Around 52 % of the international and 33 % of the Swiss metamizole-associated hematological ADR occurred within a latency time of ≤7 days. More women were affected. The annual number of hematological reports and those with fatal outcome increased over the last years parallel to metamizole sales figures. In Switzerland, the minimal incidence rate of agranulocytosis was 0.46–1.63 cases per million person-days of use (2006–2012). Female sex, old age, pancytopenia, and co-medication with methotrexate were striking characteristics of the seven Swiss fatal cases.

Conclusions

Metamizole-associated hematological ADR remain frequently reported. This is underscored by increasing annual reporting rates, which mainly reflect growing metamizole use. Early detection of myelotoxicity and avoidance of other myelotoxic substances such as methotrexate are important measures for preventing fatalities.

Keywords

Metamizole (dipyrone) Agranulocytosis Hematological safety Pharmacovigilance 

Notes

Acknowledgments

The authors would like to thank Sara Hult, member of the analysis team of the Uppsala Monitoring Centre, the WHO Collaborating Centre for International Drug Monitoring, for providing the data and for answering our questions. We also would like to thank Guy Levy from the Vigilance Unit of Swissmedic for his collaboration. We thank also Sanofi-Aventis SA, Streuli Pharma AG, and Sintetica SA for providing the sales figures of their metamizole preparations in Switzerland. We thank also the Senglet-Foundation, the foundation for the promotion of young pharmaceutical researchers in Basel, for their financial support.

Author contribution

Performed research: LB, AT, PE, ARB. Analyzed data: LB, AT, MH, SK, ARB. Wrote manuscript: LB, SK, ARB. All authors contributed to the review and final approval of the manuscript.

Conflict of interest

The authors declare that there are no conflicts of interest regarding this work.

Supplementary material

228_2014_1781_MOESM1_ESM.docx (27 kb)
ESM 1 (DOCX 27.0 kb)

References

  1. 1.
    Gierse JK, Koboldt CM, Walker MC, Seibert K, Isakson PC (1999) Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem J 339(Pt 3):607–614PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Campos C, de Gregorio R, Garcia-Nieto R, Gago F, Ortiz P, Alemany S (1999) Regulation of cyclooxygenase activity by metamizol. Eur J Pharmacol 378(3):339–347PubMedCrossRefGoogle Scholar
  3. 3.
    Hinz B, Cheremina O, Bachmakov J, Renner B, Zolk O, Fromm MF et al (2007) Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. FASEB J 21(10):2343–2351. doi: 10.1096/fj.06-8061com PubMedCrossRefGoogle Scholar
  4. 4.
    Pierre SC, Schmidt R, Brenneis C, Michaelis M, Geisslinger G, Scholich K (2007) Inhibition of cyclooxygenases by dipyrone. Br J Pharmacol 151(4):494–503. doi: 10.1038/sj.bjp.0707239 PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Rogosch T, Sinning C, Podlewski A, Watzer B, Schlosburg J, Lichtman AH et al (2012) Novel bioactive metabolites of dipyrone (metamizol). Bioorg Med Chem 20(1):101–107. doi: 10.1016/j.bmc.2011.11.028 PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    (1986) Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. The International Agranulocytosis and Aplastic Anemia Study. JAMA 256(13):1749–1757Google Scholar
  7. 7.
    Bottiger LE, Westerholm B (1973) Drug-induced blood dyscrasias in Sweden. Br Med J 3(5875):339–343PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Hedenmalm K, Spigset O (2002) Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole). Eur J Clin Pharmacol 58(4):265–274. doi: 10.1007/s00228-002-0465-2 PubMedCrossRefGoogle Scholar
  9. 9.
    Chan TY, Chan AW (1996) Aminopyrine-induced blood dyscrasias—still a problem in many parts of the world. Pharmacoepidemiol Drug Saf 5(4):215–219. doi: 10.1002/(SICI)1099-1557(199607)5:4<215::AID-PDS208>3.0.CO;2-5 PubMedCrossRefGoogle Scholar
  10. 10.
    Zukowski M, Kotfis K (2009) Safety of metamizole and paracetamol for acute pain treatment. Anestezjol Intens Ter 41(3):170–175PubMedGoogle Scholar
  11. 11.
    Andrade SE, Martinez C, Walker AM (1998) Comparative safety evaluation of non-narcotic analgesics. J Clin Epidemiol 51(12):1357–1365PubMedCrossRefGoogle Scholar
  12. 12.
    Solal-Celigny P (1994) Abnormal hematologic values. In: Benichou C (ed) Adverse drug reactions: a practical guide to diagnosis and management. John Wiley & Sons, Chichester, pp 13–30Google Scholar
  13. 13.
    (1999) Reporting adverse drug reactions. Definitions of terms and criteria for their use. Council for International Organizations of Medical Sciences (CIOMS), SwitzerlandGoogle Scholar
  14. 14.
    Ibanez L, Vidal X, Ballarin E, Laporte JR (2005) Population-based drug-induced agranulocytosis. Arch Intern Med 165(8):869–874. doi: 10.1001/archinte.165.8.869 PubMedCrossRefGoogle Scholar
  15. 15.
    Theophile H, Begaud B, Martin K, Laporte JR, Capella D (2004) Incidence of agranulocytosis in Southwest France. Eur J Epidemiol 19(6):563–565PubMedCrossRefGoogle Scholar
  16. 16.
    Maj S, Lis Y (2002) The incidence of metamizole sodium-induced agranulocytosis in Poland. J Int Med Res 30(5):488–495PubMedCrossRefGoogle Scholar
  17. 17.
    van der Klauw MM, Goudsmit R, Halie MR, van’t Veer MB, Herings RM, Wilson JH et al (1999) A population-based case-cohort study of drug-associated agranulocytosis. Arch Intern Med 159(4):369–374PubMedCrossRefGoogle Scholar
  18. 18.
    Andersohn F, Konzen C, Garbe E (2007) Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 146(9):657–665PubMedCrossRefGoogle Scholar
  19. 19.
    Ibanez L, Vidal X, Ballarin E, Laporte JR (2005) Agranulocytosis associated with dipyrone (metamizol). Eur J Clin Pharmacol 60(11):821–829. doi: 10.1007/s00228-004-0836-y PubMedCrossRefGoogle Scholar
  20. 20.
    Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA (1993) Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 329(3):162–167. doi: 10.1056/NEJM199307153290303 PubMedCrossRefGoogle Scholar
  21. 21.
    Andres E, Maloisel F (2008) Idiosyncratic drug-induced agranulocytosis or acute neutropenia. Curr Opin Hematol 15(1):15–21. doi: 10.1097/MOH.0b013e3282f15fb9 PubMedCrossRefGoogle Scholar
  22. 22.
    Swiss product information online. Documed AG, Basel. 2013. www.compendium.ch. Accessed 18 Dec 2013
  23. 23.
    Moore N, Hall G, Sturkenboom M, Mann R, Lagnaoui R, Begaud B (2003) Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol Drug Saf 12(4):271–281. doi: 10.1002/pds.848 PubMedCrossRefGoogle Scholar
  24. 24.
    Backstrom M, Hagg S, Mjorndal T, Dahlqvist R (2002) Utilization pattern of metamizole in northern Sweden and risk estimates of agranulocytosis. Pharmacoepidemiol Drug Saf 11(3):239–245. doi: 10.1002/pds.697 PubMedCrossRefGoogle Scholar
  25. 25.
    Hazell L, Shakir SA (2006) Under-reporting of adverse drug reactions: a systematic review. Drug Saf Int J Med Toxicol Drug Experience 29(5):385–396CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Lea S. Blaser
    • 1
  • Alexandra Tramonti
    • 1
  • Pascal Egger
    • 2
  • Manuel Haschke
    • 1
  • Stephan Krähenbühl
    • 1
    Email author
  • Alexandra E. Rätz Bravo
    • 1
    • 3
  1. 1.Division of Clinical Pharmacology and ToxicologyUniversity HospitalBaselSwitzerland
  2. 2.Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical SciencesUniversity of BaselBaselSwitzerland
  3. 3.Regional Pharmacovigilance CenterUniversity HospitalBaselSwitzerland

Personalised recommendations